NCT05996159 Pulmonary Vein Isolation Strategy of Very High Power Short Duration in Patients With Paroxysmal Atrial Fibrillation
| NCT ID | NCT05996159 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Paroxysmal Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-11-07 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2023-11-07 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the effect of reducing ablation time for a hybrid approach of vHPSD and AI-guided ablation using the QDOT Micro catheter in PVI among patients with PAF.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing PVI for PAF Exclusion Criteria: * Aged less than 19 years * Patients with persistent AF * Patients with previous ablation or surgery for AF * Patients with intracardiac thrombus or thromboembolic events within the previous 90 days * Patients with cardiac surgery or acute coronary syndrome within the previous 90 days * Patients with contraindication(s) for using oral anticoagulants * Patients with LA anteroposterior diameter of more than 55 mm * Patients with left ventricular ejection fraction less than 35% * Pregnants or those who plan to become pregnant during the study * Life expectancy less than a year
Contact & Investigator
Eue-Keun Choi, M.D. Ph.D.
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT05996159 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Paroxysmal Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05996159 currently recruiting?
Yes, NCT05996159 is actively recruiting participants. Contact the research team at choiek417@gmail.com for enrollment information.
Where is the NCT05996159 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05996159 clinical trial?
NCT05996159 is sponsored by Seoul National University Hospital. The principal investigator is Eue-Keun Choi, M.D. Ph.D. at Seoul National University Hospital. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.